Evidence map›Paper›PMID 35664764›Full record

ArticleFrontiers in oncology2022

Defining a Standard Set of Patient-Reported Outcomes for Patients With Advanced Ovarian Cancer.

Vicente Escudero-Vilaplana, Elsa Bernal, Gema Casado, Roberto Collado-Borrell, Raúl Diez-Fernández, Ana Beatriz Fernández Román, Carlos Folguera, Lucía González-Cortijo, Marta Herrero-Fernández, Gloria Marquina and 7 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Multidisciplinary management of advanced ovarian cancer in Spain: expert recommendations for achieving maximum survival and improving patient care.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Vicente Escudero-VilaplanaHospital Pharmacy, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Elsa BernalDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Gema CasadoHospital Pharmacy, Hospital Universitario La Paz, Madrid, Spain.
Roberto Collado-BorrellHospital Pharmacy, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Raúl Diez-FernándezHospital Pharmacy, Hospital Universitario de Getafe, Getafe, Spain.
Ana Beatriz Fernández RománHospital Pharmacy, Hospital Universitario de Fuenlabrada, Madrid, Spain.
Carlos FolgueraHospital Pharmacy, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain.
Lucía González-CortijoBreast and Gynecological Tumor Unit, Hospital Universitario Quirónsalud Madrid, Madrid, Spain.
Marta Herrero-FernándezHospital Pharmacy, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain.
Gloria MarquinaDepartment of Medical Oncology, Hospital Clinico san Carlos, Madrid, Spain.
Concepción Martínez NietoHospital Pharmacy, Hospital Universitario La Princesa, Madrid, Spain.
Miguel Angel RodríguezHospital Pharmacy, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Ana Rosa RubioHospital Pharmacy, Hospital Universitario de Toledo, Toledo, Spain.
Patricia Sanmartin-FenolleraHospital Pharmacy, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain.
Maria José Vazquez CastilloHospital Pharmacy, Hospital Universitario de Móstoles, Móstoles, Spain.
Marta ComellasOutcomes'10, Castellón de la Plana, Spain.
Eva Maria GuerraDepartment of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Advanced ovarian cancer (AOC) and its treatment cause several symptoms and impact on patients' health-related quality of life (HRQoL). We aim to reach a consensus on the most relevant patient-reported outcome (PROs), the corresponding measures (PROMs), and measurement frequency during AOC patients' follow-up from patients' and healthcare professionals' (HCP) perspective. Methods: The project comprised five steps: 1) a literature review, 2) a focus group with patients, 3) a nominal group with HCP, 4) two round-Delphi consultations with patients and HCP, and 5) a final meeting with HCP. Delphi questionnaire was elaborated based on literature review, focus group (n=5 patients), and nominal group (n=16 HCP). The relevance of each PRO and the appropriateness (A) and feasibility (F) of the proposed PROM were assessed (Likert scale 1=strongly agree; 9=strongly disagree). The consensus was reached when at least 75% of the panelists rated it as 'relevant', 'appropriate', or 'feasible' (score 7-9). Results: A total of 56 HCP [51.8% Hospital Pharmacy; 41.1% Oncology; 3.6% Nursing; and 3.6% Psycho-oncology; mean time in specialty 12.5 (8.0) years] and 10 AOC patients [mean time diagnosis 5.4 (3.0) years] participated in the 1 Conclusions: The consensus reached represents the first step towards including the patient's perspective in AOC follow-up. The standardized collection of PROs in clinical practice may contribute to optimizing the follow-up of these patients and thus improving the quality of care.

Indexed as

ovarian cancerpatient-centered carepatient centricitypatient-reported outcome measurespatient-reported outcomes

Identifiers

PMID35664764
PMCPMC9159390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.